Treatment of prehypertension among adults with HIV
Authors:
Open Access
- 13 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 39 (3) , 261-269
Abstract
Objective: Elevated blood pressure (BP), even at prehypertensive levels, increases cardiovascular disease risk among people with HIV (PWH); yet international guidelines in low-income countries recommend treatment initiation at BP at least 140/90 mmHg. We determined the efficacy, feasibility, and acceptability of treating prehypertension in PWH in Haiti. Design: An unblinded randomized clinical trial (enrolled April 2021–March 2022) with 12-month follow-up. Setting: GHESKIO Centres, Port-au-Prince, Haiti. Participants: Two hundred fifty adults with HIV with prehypertension (SBP 120–138 or DBP 80–89) not on medication, aged 18–65 years, virally suppressed, and without pregnancy, diabetes, or kidney disease. Intervention: Participants were randomized to treatment (amlodipine 5 mg) or control (no amlodipine unless two BP ≥140/90 mmHg). Main outcome measure: Primary outcome was mean change in SBP between intervention versus control groups from enrollment to 12 months. Results: Among 250 adults, median age was 49 years, 40.8% were women. Baseline median BP was 129/78 mmHg intervention versus 128/77 mmHg control. After 12 months, the difference in mean change between study groups for SBP was -5.9 mmHg [95% confidence interval (95% CI) -8.8 to -3.0] and for DBP was -5.5 mmHg (95% CI -7.9 to -3.2). At 12 months, 5.6% intervention and 23.0% control participants developed incident hypertension (hazard ratio 0.18; 95% CI 0.07–0.47). There were no differences in viral load suppression at 12 months or drug-related serious adverse events. Intervention acceptability was high among providers and participants in qualitative interviews. Conclusion: In PWH in a resource-poor setting, prehypertension treatment was feasible, acceptable, and effective in reducing mean SBP and incident hypertension. Registration: Clinicaltrials.gov NCT04692467 ExportKeywords
This publication has 22 references indexed in Scilit:
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisThe Lancet, 2021
- Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk FactorsJAMA Cardiology, 2020
- Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysisJournal of the American Society of Hypertension, 2017
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysisThe Lancet, 2016
- A Randomized Trial of Intensive versus Standard Blood-Pressure ControlNew England Journal of Medicine, 2015
- Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million peopleThe Lancet, 2014
- Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk PatientsNew England Journal of Medicine, 2008
- Feasibility of Treating Prehypertension with an Angiotensin-Receptor BlockerNew England Journal of Medicine, 2006
- Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood PressureJAMA, 2004
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000